一種新型基因探針使用熒光原位雜交技術來檢測患者樣本中骨髓細胞的染色體性別。這種自動應用方法已經獲得了美國食品藥品管理局的許可。

骨髓移植是治療白血病以及其它血液系統癌癥的重要方法。進行骨髓供體與受體之間細胞比例的比較，主要用于評估性別錯配骨髓移植受體的移植成功率。這種探針是標準染色體組型分析（或者叫做常規染色體分析）的補充。

對X和Y染色體的分析在自動CytoVison系統上進行，該系統是應用影像(San Jose, CA, USA; www.aicorp.com)公司的產品。該系統使用Vysis公司(Downer’s Grove, IL)的CEP X光譜橙色/CEP Y光譜綠色DNA探針試劑盒。

Applied Imaging公司首席執行官Robin Stracey指出：“這項技術為我們客戶改進白血病的治療提供了一項重要的診斷工具。我們的目的是為我們的客戶提供廣泛選擇，有助于顯著改善各種癌癥的診斷、治療以及監測。”
 
Genetic Test Aids Bone Marrow Transplants
 
A new genetic probe uses fluorescence in situ hybridizarion (FISH) technology to identify the chromosomal gender of bone marrow cells within a patient sample. The automated application has been cleared by the U.S. Food and Drug Administration (FDA).

Bone marrow transplantation is an important therapeutic strategy in the management of leukemias and other blood-based cancers. A comparison of the proportion of cells belonging to the bone marrow donor versus the recipient is used to evaluate engraftment success in recipients of sex-mismatched bone marrow transplants. The probe is an adjunct to standard karyotyping, or routine chromosome analysis.

This analysis of the X and Y chromosomes is made on the automated CytoVision system of Applied Imaging (San Jose, CA, USA; www.aicorp.com). The application employs the CEP X spectrum orange/CEP Y spectrum green DNA probe kit from Vysis, Inc. (Downer’s Grove, IL).

“This application provides our customers with an important diagnostic tool to better manage leukemias,” noted Robin Stracey, CEO of Applied Imaging. “Our aim is to provide our customers with a broad array of solutions that help to improve significantly the diagnosis, therapy selection, and monitoring of a wide variety of cancerous conditions.”